Lineage Cell Therapeutics, Inc.

127 articles about Lineage Cell Therapeutics, Inc.

• Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

  3/10/2022

  Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported financial and operating results for the fourth quarter and full year 2021.

• Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results and Provide Business Update on March 10, 2022

  3/1/2022

  Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its fourth quarter and full year 2021 financial and operating results on Thursday, March 10, 2022, following the close of the U.S. financial markets.

• Lineage to Present at B. Riley Securities 2022 Virtual Oncology Conference on January 27, 2022

  1/24/2022

  Lineage Cell Therapeutics, Inc. announced that Brian M. Culley, Lineage’s Chief Executive Officer, will present at the B. Riley Securities 2022 Virtual Oncology Conference, in a fireside chat hosted by Mayank Mamtani, Managing Director, Senior Biotech Research Analyst and Group Head of Healthcare Research at B. Riley Securities.

• Lineage Cell Therapeutics to Present at H.C. Wainwright Bioconnect Virtual Conference

  1/4/2022

  Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that Brian M. Culley, Chief Executive Officer will be presenting at the H.C. Wainwright Bioconnect Virtual Conference.

• Lineage Establishes Exclusive Worldwide Collaboration With Genentech for the Development and Commercialization of OpRegen® RPE Cell Therapy for the Treatment of Ocular Disorders

  12/20/2021

  Lineage Cell Therapeutics, Inc., announced that Lineage and its subsidiary, Cell Cure Neurosciences Ltd., have entered into an exclusive worldwide collaboration and license agreement with Roche and Genentech for the development and commercialization of a retinal pigment epithelium cell therapy for the treatment of ocular disorders, including advanced dry age-related macular degeneration with geographic atrophy.

• Lineage Reports Fourth Case of Retinal Tissue Restoration With OpRegen®

  11/30/2021

  Lineage Reports Fourth Case of Retinal Tissue Restoration With OpRegen ® .

• OpRegen® Clinical Data Presented at 125th Annual American Academy of Ophthalmology Meeting by Michael S. Ip, M.D.

  11/15/2021

  OpRegen ® Clinical Data Presented at 125th Annual American Academy of Ophthalmology Meeting by Michael S. Ip, M.D.

• Lineage Reports Third Quarter 2021 Financial Results and Highlights Progress From Clinical Cell Therapy Programs

  11/10/2021

  Lineage Cell Therapeutics, Inc. today reported financial and operating results for the third quarter 2021.

• Lineage Cell Therapeutics to Report Third Quarter 2021 Financial Results and Provide Business Update on November 10, 2021

  11/3/2021

  Lineage Cell Therapeutics, Inc. today announced that it will report its third quarter 2021 financial and operating results on Wednesday, November 10, 2021, following the close of the U.S. financial markets.

• OpRegen® Data Update to Be Featured at 2021 American Academy of Ophthalmology Annual Meeting in Presentation by Michael S. Ip, M.D.

  10/26/2021

  OpRegen ® Data Update to Be Featured at 2021 American Academy of Ophthalmology Annual Meeting in Presentation by Michael S. Ip, M.D.

• Lineage to Be Featured in B. Riley Securities Fall 2021 “Growth Biotech Best Ideas” Virtual Series on October 18, 2021

  10/18/2021

  Lineage Cell Therapeutics, Inc. today announced that Lineage will be featured in the B. Riley Securities Fall 2021 “Growth Biotech Best Idea” Virtual Series

• Promising New OpRegen® Clinical Data Featured at 54th Annual Retina Society Meeting in Podium Presentation by Christopher D. Riemann, M.D.

  9/30/2021

  Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, reported today that updated interim results from a Phase 1/2a clinical study of its lead product candidate, OpRegen®,

• Lineage to Present at the 2021 Cantor Virtual Global Healthcare Conference on September 27, 2021

  9/20/2021

  Lineage Cell Therapeutics, Inc. today announced that Brian M. Culley, the Company’s Chief Executive Officer, will be presenting at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference in a fireside chat hosted by Kristen Kluska, Director, Equity Research on September 27th, 2021.

• Data From Ongoing Clinical Trial Continues to Demonstrate a Single Administration of OpRegen® Can Provide Anatomical and Functional Improvements in Patients With Dry AMD With Geographic Atrophy

  9/15/2021

  Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported updated interim results from its ongoing, 24-patient Phase 1/2a clinical study of its lead product candidate, OpRegen.

• Opregen® Data Update Will Be Featured at 54th Annual Retina Society Meeting in Podium Presentation by Christopher D. Riemann, M.D.

  9/13/2021

  Lineage Cell Therapeutics, Inc. reported that updated interim results from a Phase 1/2a study of its lead product candidate, OpRegen®, a retinal pigment epithelium cell transplant therapy currently in development for the treatment of dry age-related macular degeneration, will be featured in a podium presentation at the 54th Annual Scientific Meeting of the Retina Society, to be held at the Ritz-Carlton Hotel in Chicago, IL.

• Lineage Announces Appointment of General Counsel

  9/1/2021

  Lineage Cell Therapeutics, Inc. today announced that it has appointed George A. Samuel III as Lineage’s General Counsel and Corporate Secretary.

• Lineage Reports Second Quarter 2021 Financial Results and Highlights Additional Progress From Clinical Cell Therapy Programs

  8/12/2021

  Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported financial and operating results for the second quarter 2021.

• Lineage to Present at the H.C. Wainwright Ophthalmology Conference on August 17, 2021

  8/10/2021

  Lineage Cell Therapeutics, Inc. today announced that Brian M. Culley, the Company’s Chief Executive Officer, will be participating in and presenting at the H.C. Wainwright & Co. Inc. Virtual Ophthalmology Conference .

• Lineage Cell Therapeutics to Report Second Quarter 2021 Financial Results and Provide Business Update on August 12, 2021

  8/5/2021

  Lineage Cell Therapeutics, Inc. today announced that it will report its second quarter 2021 financial and operating results on Thursday, August 12, 2021, following the close of the U.S. financial markets.

• OpRegen® Clinical Data Continues to Demonstrate Functional and Anatomical Improvements in Patients With Dry AMD With Geographic Atrophy

  7/20/2021

  OpRegen ® Clinical Data Continues to Demonstrate Functional and Anatomical Improvements in Patients With Dry AMD With Geographic Atrophy